Omthera asserts Epanova superiority but US filing delayed to next year
This article was originally published in Scrip
Omthera Pharmaceuticals is determined to show that Epanova, its free fatty acid formulation of omega-3 that contains both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is superior to Amarin's recently approved ethyl ester omega-3 Vascepa (icosapent ethyl).
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.